The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.
Eight children with severe autoimmune diseases who did not respond to conventional therapies were able to completely stop ...
AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...
Litifilimab, a humanized immunoglobulin G1 monoclonal antibody that targets blood dendritic cell antigen 2, has been granted ...
The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results